- About UsOur Story, Our Team & Support Information
- What We DoAdvocacy to Achieve the End of AIDS
- Advocate for Policies and Actions
- Build Rapid-Response Networks
- Advocacy Fellows Program
- PxROAR (Research, Outreach, Advocacy and Representation)
- Women's HIV Prevention Tracking Project (WHiPT)
- Advocacy Partners Forum
- Improve Research Conduct
- Provide Tools for Decision-Making
- Translate & Share the Latest Information
- Our FocusInterventions to End the Epidemic
- Combination Prevention
- Male and Female Condoms
- Hormonal Contraceptives and HIV
- Multipurpose Prevention Technologies
- HIV Vaccine
- Voluntary Medical Male Circumcision
- How Research Happens
- ResourcesPublications, Infographics, Events & More
- MediaInformation & Resources for the Press
- Our BlogPrevention News & Perspective
One woman has many choices, many needs. Family planning and HIV prevention must be integrated.
Many women at risk for HIV are equally, if not more, concerned about avoiding or postponing pregnancy. Some research suggests that specific injectable contraceptives (progestogen-only products like DMPA and Depo-Provera) increase women’s risk of acquiring HIV. There are other studies that do not show this link between DMPA and HIV risk. There is an ongoing global discussion about how to proceed with HIV prevention and family planning programs in the context of this uncertainty. There is an urgent need to ensure that women who want and need effective family planning methods are able to access them. Unplanned pregnancies carry a high risk of maternal mortality and morbidity. There is an equally compelling need to ensure that women receive full information about the risks and benefits of different methods—including potential HIV risk—and that they have access to a range of choices.
It is important to note that these data are of primary relevance to women living in southern and eastern Africa in countries with high HIV prevalence and incidence and high use of DMPA. In these settings, some countries, like South Africa, are already moving to update their contraceptive policies to reflect the uncertainty about progestogen-only contraceptives like Depo-Provera. There is also ongoing discussion about the kinds of research that could be conducted—from randomized trials to observational studies—to learn more about this key question.
In this context, it is critical that the voices and priorities of African women guide the conversation. AVAC works in partnership with groups and individuals in East and Southern Africa to prioritize and amplify womens’ issues and concerns.
What We're Reading